Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.35 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24794753 | 0.84 | GPR119 (0.37) | MAPTALDH1A1LMNAHSD11B1CHRM2 | |
| SCHEMBL29709695 | 0.84 | GPR119 (0.37) | MAPTALDH1A1LMNAHSD11B1CHRM2 | |
| SCHEMBL22471536 | 0.84 | CHRM2 (0.42) | MAPTALDH1A1HSD11B1CHRM2CHRM1 | |
| SCHEMBL28730740 | 0.84 | CHRM2 (0.42) | MAPTALDH1A1HSD11B1CHRM2CHRM1 | |
| SCHEMBL24223887 | 0.84 | CHRM2 (0.42) | MAPTALDH1A1HSD11B1CHRM2CHRM1 | |
| SCHEMBL17548160 | 0.84 | KCNK3 (0.43) | HSD11B1CHRM2CHRM1CHRM3WDR5 | |
| SCHEMBL3034148 | 0.83 | SLC6A2 (0.46) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL17197423 | 0.83 | CHEK1 (0.39) | MAPTALDH1A1LMNAPOLBHSD11B1 | |
| SCHEMBL15244232 | 0.83 | KMT2A (0.42) | MAPTALDH1A1LMNAJAK1WDR5 | |
| SCHEMBL2072369 | 0.81 | GPR119 (0.43) | HSD11B1CHRM2CHRM1CHRM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
| EP-3402791-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-18 | — | — | US | disclosed |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-19 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-17 | — | — | US | disclosed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | disclosed |
| WO-2017123542-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-20 | — | — | WO | disclosed |
| US-8975398-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-03-10 | — | — | US | disclosed |
| WO-2013170115-A1 | PYRIDAZINE AND PYRIDINE DERIVATIVES AS NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20130303510-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303509-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2655357-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | Merck Serono S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | MERCK SERONO S.A. - INTELLECTUAL PROPERTY (CH) | 2013-10-17 | — | — | US | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012084704-A1 | INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS | MERCK SERONO S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | MAPT 3804/4885ALDH1A1 350/4885LMNA 4294/4885 |
| US-20180298021-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | MAPT 3804/4885ALDH1A1 350/4885LMNA 4294/4885 |
| US-20170233401-A1 | SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | AR, SHBG, NR5A1 | MAPT 3804/4885ALDH1A1 350/4885LMNA 4294/4885 |
| US-10000502-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | MAPT 3804/4885ALDH1A1 350/4885LMNA 4294/4885 |
| US-20130303510-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPT 582/4885ALDH1A1 1573/4885LMNA 711/4885 |
| US-20130274241-A1 | INDAZOLYL TRIAZOL DERIVATIVES | NFATC1, IL5, CD4 | MAPT 2022/4885ALDH1A1 875/4885LMNA 4562/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | MAPT 3804/4885ALDH1A1 350/4885LMNA 4294/4885 |
| US-20130303509-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | MAPT 582/4885ALDH1A1 1573/4885LMNA 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.